Impacts of cytogenetic categories in the Revised International Prognostic Scoring System on the prognosis of primary myelodysplastic syndromes: Results of a single-center study

Leukemia and Lymphoma

Volumn 53, Issue 5, 2012, Pages 940-946

  Qu, Shiqiang ^a   Xu, Zefeng ^a   Zhang, Yue ^a   Qin, Tiejun ^a   Zhang, Tianjiao ^a   Cui, Rui ^a   Xiao, Zhijian ^a,b  

^a PEKING UNION MEDICAL COLLEGE   (China)

^b INSTITUTE OF HEMATOLOGY AND BLOOD DISEASES HOSPITAL   (China)

Author keywords

cytogenetics; karyotype; Myelodysplastic syndromes; prognosis; Revised IPSS

Indexed keywords

ADOLESCENT; ADULT; AGED; ARTICLE; CHINESE; CHROMOSOME ANALYSIS; CHROMOSOME BANDING PATTERN; CHROMOSOME DELETION; CHROMOSOME REARRANGEMENT; CHROMOSOME TRANSLOCATION; FEMALE; GENE FREQUENCY; HUMAN; INTERNATIONAL PROGNOSTIC SCORING SYSTEM; KARYOTYPE; MAJOR CLINICAL STUDY; MALE; MYELODYSPLASTIC SYNDROME; PRIORITY JOURNAL; PROGNOSIS; RETROSPECTIVE STUDY; RISK ASSESSMENT; SURVIVAL TIME; TRISOMY 8;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; ASIAN CONTINENTAL ANCESTRY GROUP; CHROMOSOMES, HUMAN, PAIR 8; CYTOGENETIC ANALYSIS; FEMALE; HUMANS; MALE; MIDDLE AGED; MYELODYSPLASTIC SYNDROMES; PROGNOSIS; RISK ASSESSMENT; SURVIVAL RATE; TRISOMY; YOUNG ADULT;

EID: 84860002247     PISSN: 10428194     EISSN: 10292403     Source Type: Journal    
DOI: 10.3109/10428194.2011.634049     Document Type: Article

References (37)

1. Komrokji RS, Zhang L, Bennett JM. Myelodysplastic syndromes classification and risk stratification. Hematol Oncol Clin North Am 2010;24:443-457.
2. Cazzola M, Malcovati L. Prognostic classification and risk assessment in myelodysplastic syndromes. Hematol Oncol Clin North Am 2010;24:459-468.
3. Garcia-Manero G. Prognosis of myelodysplastic syndromes. Hematology Am Soc Hematol Educ Program 2010:330-337.
4. B ennett JM, Catovsky D, Daniel MT, et al. Proposals for the classification of the myelodysplastic syndromes. Br J Haematol 1982;51:189-199. (Pubitemid 12073508)
5. V ardiman JW, Harris NL, Brunning RD. The World Health Organization (WHO) classification of the myeloid neoplasms. Blood 2002;100:2292-2302.
6. B running RD, Orazi A, Germing U, et al. Myelodysplastic syndromes/ neoplasms, overview. In: Swerdlow SH, Campo E, Harris NL, editors. WHO classification of tumours of hamatopoietic and lymphoid tissues. Lyon, France: IARC; 2008. p 88.
7. M ufti GJ, Stevens JR, Oscier DG, et al. Myelodysplastic syndromes: a scoring system with prognostic significance. Br J Haematol 1985;59:425-433. (Pubitemid 15132943)
8. S anz GF, Sanz MA, Vallespi T, et al. Two regression models and a scoring system for predicting survival and planning treatment in myelodysplastic syndromes: a multivariate analysis of prognostic factors in 370 patients. Blood 1989;74:395-408. (Pubitemid 19187457)
9. A ul C, Gattermann N, Heyll A, et al. Primary myelodysplastic syndromes:analysis of prognostic factors in 235 patients and proposal for an improved scoring system. Leukemia 1992;6:52-59.
10. M orel P, Hebbar M, Lai JL, et al. Cytogenetic analysis has strong independent prognostic value in de novo myelodysplastic syndromes and can be incorporated in a new scoring system: a report on 408 cases. Leukemia 1993;9:1315-1323. (Pubitemid 23291068)
11. T oyama K, Ohyashiki K, Yoshida Y, et al. Clinical implications of chromosome abnormalities in 401 patients with myelodysplastic syndromes: a multicentric study in Japan. Leukemia 1993;7:499-508. (Pubitemid 23139850)
12. P arlier V, van Melle G, Beris P, et al. Prediction of 18-month survival in patients with primary myelodysplastic syndrome. A regression model and scoring system based on the combination of chromosome findings and the Bournemouth score. Cancer Genet Cytogenet 1995;81:158-165.
13. G reenberg P, Cox C, LeBeau MM, et al. International scoring system for evaluating prognosis in myelodysplastic syndromes. Blood 1997;89:2079-2088. (Pubitemid 27132124)
14. M alcovati L, Germing U, Kuendgen A, et al. Time-dependent prognostic scoring system for predicting survival and leukemic evolution in myelodysplastic syndromes. J Clin Oncol 2007;25:3503-3510. (Pubitemid 47315575)
15. K antarjian H, O' B rien S, Ravandi F, et al. Proposal for a new risk model in myelodysplastic syndrome that accounts for events not considered in the original International Prognostic Scoring System. Cancer 2008;113:1351-1361.
16. H aase D. Cytogenetic features in myelodysplastic syndromes. Ann Hematol 2008;87:515-526.
17. T ricot G, Boogaerts MA, De Wolf-Peeters C, et al. The myelodysplastic syndromes: different evolution patterns based on sequential morphological and cytogenetic investigations. Br J Haematol 1985;59:659-670. (Pubitemid 15133658)
18. K napp RH, Dewald GW, Pierre RV. Cytogenetic studies in 174 consecutive patients with preleukemic or myelodysplastic syndromes. Mayo Clin Proc 1985;60:507-516. (Pubitemid 16241711)
19. J acobs RH, Cornbleet MA, Vardiman JW, et al. Prognostic implications of morphology and karyotype in primary myelodysplastic syndromes. Blood 1986;67:1765-1772. (Pubitemid 16075988)
20. Y unis JJ, Lobell M, Arnesen MA, et al. Refined chromosome study helps define prognostic subgroups in most patients with primary myelodysplastic syndromes and acute myelogenous leukemia. Br J Haematol 1988;68:189-194. (Pubitemid 18078465)
21. B illströ m R, Tiede T, Hansen S, et al. Bone marrow karyotype and prognosis in primary myelodysplastic syndromes. Eur J Haematol 1988;41:341-346. (Pubitemid 19003749)
22. Nowell PC, Besa EC. Prognostic significance of single chromosome abnormalities in preleukemic states. Cancer Genet Cytogenet 1989;42:1-7. (Pubitemid 19251572)
23. W hite AD, Hoy TG, Jacobs A. Extended cytogenetic follow-up and clinical progress in patients with myelodysplastic syndromes (MDS). Leuk Lymphoma 1994;12:401-412. (Pubitemid 24082130)
24. H aase D, Germing U, Schanz J, et al. New insights into the aprognostic impact of the karyotype in MDS and correlation with subtypes: evidence from a core dataset of 2124 patients. Blood 2007;110:4385-4395. (Pubitemid 351377805)
25. S chanz J, Tü chler H, Sole F, et al. Proposal of a new, comprehensive cytogenetic scoring system for primary MDS. Haematologica 2010;95(Suppl. 2): Abstract 535.
26. Greenberg P, Tuechler H, Schanz J, et al. Revised International Prognostic Scoring System (IPSS-R), developed by the International Prognostic Working Group for Prognosis in MDS (IWG-PM). Leuk Res 2011;35(Suppl. 1): Abstract 14.
27. M itelman F. An International System for Human Cytogenetic Nomenclature. Recommendations of the International Standing Committee on Human Cytogenetic Nomenclature. Memphis, TN: S. Karger; 1995.
28. C hun K, Hagemeijer A, Iqbal A, et al. Implementation of standardized international karyotype scoring practices is needed to provide uniform and systematic evaluation for patients with myelodysplastic syndrome using IPSS criteria: an International Working Group on MDS Cytogenetics Study. Leuk Res 2010;34:160-165.
29. Valent P, Horny HP, Bennett JM, et al. Definitions and standards in the diagnosis and treatment of the myelodysplastic syndromes: consensus statements and report from a working conference. Leuk Res a2007;31:727-736. (Pubitemid 46855901)
30. Chen B, Zhao WL, Jin J, et al. Clinical and cytogenetic features of a508 Chinese patients with myelodysplastic syndrome and comparison with those in Western countries. Leukemia 2005;19:767-775. (Pubitemid 40663096)
31. Solé F, Espinet B, Sanz GF, et al. Incidence, characterization and prognostic significance of chromosomal abnormalities in 640 patients with primary myelodysplastic syndromes. Br J Haematol 2000;108:346-356. (Pubitemid 30143651)
32. Sol é F, Luno E, Sanzo C, et al. Identification of novel cytogenetic markers with prognostic significance in a series of 968 patients with primary myelodysplastic syndromes. Haematologica 2005;90:1168-1178. (Pubitemid 41375276)
33. S chanz J, Steidl C, Fonatsch C, et al. Coalesced multicentric analysis of 2,351 patients with myelodysplastic syndromes indicates an underestimation of poor-risk cytogenetics of myelodysplastic syndromes in the International Prognostic Scoring System. J Clin Oncol 2011;29:1963-1970.
34. B ernasconi P, Klersy C, Boni M, et al. World Health Organization classification in combination with cytogenetic markers improves the prognostic stratification of patients with de novo primary myelodysplastic syndromes. Br J Haematol 2007;137:193-205. (Pubitemid 46537628)
35. Pierre RV, Catovsky D, Mufti GJ, et al. Clinical-cytogenetic correlations in myelodysplasia (preleukemia). Cancer Genet Cytogenet 1989;40:149-161.
36. B ernasconi P, Alessandrino EP, Boni M, et al. Karyotype in myelodysplastic syndromes: relations to morphology, clinical evolution and survival. Am J Hematol 1994;46:270-277. (Pubitemid 24243869)
37. O lney HJ, Le Beau MM. The cytogenetics of myelodysplastic syndromes. Best Pract Res Clin Hematol 2001;14:479-495. (Pubitemid 33019747)